IMAPAC Glossary

Hepatotoxicity describes liver injury caused by drugs, chemicals, or biological agents, ranging from mild elevations in liver enzymes to severe liver failure requiring transplantation. This toxicity may arise through direct cellular damage, immune-mediated mechanisms, mitochondrial dysfunction, or formation of reactive metabolites, with risk influenced by dose, duration, patient genetics, and comorbid conditions. Hepatotoxicity represents a leading cause of clinical trial failure and post-market withdrawals.

The pharmaceutical industry prioritises hepatotoxicity assessment throughout development due to its significant safety implications. Preclinical studies evaluate liver effects through histopathology, clinical chemistry markers, and mechanistic assays predicting injury risk. Clinical trials monitor liver function tests closely, applying stopping rules and risk management strategies when signals emerge. Drug-induced liver injury investigation requires careful causality assessment, evaluation of alternative explanations, and consideration of class effects. Regulatory agencies expect robust hepatic safety monitoring plans and appropriate labelling for identified risks. As predictive toxicology advances through human-relevant models and improved biomarkers, hepatotoxicity management remains central to developing safe therapies and maintaining regulatory confidence.

High Throughput Screening (HTS) designates automated methodologies rapidly testing large compound libraries against biological targets, enabling efficient identification of active molecules in drug discovery through miniaturised assays, robotic liquid handling, sensitive detection systems, and sophisticated data management. These platforms screen thousands to millions of compounds within days or weeks.

The pharmaceutical industry relies on HTS as foundational drug discovery tool identifying starting points for development programmes. Assay development optimises conditions for robust, reproducible performance in miniaturised formats, validating through Z-factor and signal-to-noise metrics. Screening strategies employ single-concentration primary screens followed by dose-response confirmation of active compounds. Follow-up includes counter-screening against related targets assessing selectivity, cytotoxicity evaluation, and structural cluster analysis. Alternative approaches include high-content screening incorporating imaging, fragment-based screening, and virtual screening computationally filtering libraries. As compound libraries grow and artificial intelligence enhances hit identification, HTS evolves through miniaturisation and integration with computational approaches.

High Throughput Screening (HTS) designates automated methodologies rapidly testing large compound libraries against biological targets, enabling efficient identification of active molecules in drug discovery through miniaturised assays, robotic liquid handling, sensitive detection systems, and sophisticated data management. These platforms screen thousands to millions of compounds within days or weeks, employing 384-well or 1536-well microplates with detection methods including fluorescence, luminescence, absorbance, or label-free techniques. HTS campaigns generate massive datasets requiring statistical analysis, hit confirmation, and structure-activity relationship evaluation guiding medicinal chemistry optimisation.

The pharmaceutical industry relies on HTS as foundational drug discovery tool identifying starting points for development programmes. Assay development optimises conditions for robust, reproducible performance in miniaturised formats, validating through Z-factor and signal-to-noise metrics. Library selection includes diverse compound collections, focused libraries, fragment libraries, or natural product extracts. Screening strategies employ single-concentration primary screens followed by dose-response confirmation of active compounds. Hit criteria balance activity, selectivity, and drug-like properties. Quality control includes positive and negative controls, plate uniformity assessment, and systematic error detection. Challenges include assay interference from compound properties and false positives from aggregation or fluorescence artefacts. As compound libraries grow, assay technologies improve, and artificial intelligence enhances hit identification, HTS evolves through miniaturisation and innovative detection methods.

High-Content Screening encompasses automated fluorescence microscopy-based methodologies analysing cellular phenotypes through multi-parametric image acquisition and quantitative analysis, enabling complex biological endpoint assessment beyond simple activity measurements. These platforms capture multiple fluorescent channels imaging cellular structures, organelles, or molecular markers, with image analysis algorithms extracting quantitative data across thousands of cells per condition.

The biopharmaceutical industry employs high-content screening for diverse applications requiring detailed cellular characterisation. Phenotypic drug discovery screens compound libraries without predetermined targets, identifying molecules producing desired cellular effects. Mechanism of action studies reveal compound effects on cellular processes including receptor trafficking, signalling pathway activation, or organelle morphology. Toxicity assessment uses multi-parametric imaging detecting early indicators of cytotoxicity or mitochondrial dysfunction. Cell quality control in manufacturing employs high-content imaging characterising therapeutic cell products. As imaging technologies advance and artificial intelligence improves analysis, high-content screening increasingly contributes to drug discovery, safety assessment, and mechanistic research.

High-Content Screening encompasses automated fluorescence microscopy-based methodologies analysing cellular phenotypes through multi-parametric image acquisition and quantitative analysis, enabling complex biological endpoint assessment beyond simple activity measurements. These sophisticated platforms capture multiple fluorescent channels imaging cellular structures or molecular markers, with image analysis algorithms extracting quantitative data describing morphology, localisation, intensity, or temporal dynamics across thousands of cells per condition. High-content approaches provide rich phenotypic information revealing mechanism of action, cytotoxicity, and pathway perturbations.

The biopharmaceutical industry employs high-content screening for diverse applications requiring detailed cellular characterisation. Phenotypic drug discovery screens compound libraries without predetermined targets, identifying molecules producing desired cellular effects. Mechanism of action studies employ high-content assays revealing compound effects on cellular processes including receptor trafficking, signalling pathway activation, or organelle morphology. Toxicity assessment uses multi-parametric imaging detecting early indicators of cytotoxicity or stress responses. Cell quality control in manufacturing employs high-content imaging characterising therapeutic cell products. As imaging technologies advance, artificial intelligence improves analysis, and understanding grows regarding phenotypic signatures, high-content screening increasingly contributes to drug discovery, safety assessment, and mechanistic research through comprehensive cellular characterisation.

Histidine Buffer refers to formulation systems using histidine as a buffering agent to maintain stable pH in pharmaceutical products, particularly biologics such as monoclonal antibodies and recombinant proteins. Histidine offers buffering capacity in physiologically relevant pH ranges and can support protein stability by reducing aggregation or degradation under certain conditions.

The biopharmaceutical industry frequently employs histidine buffers in injectable biologic formulations where long-term stability and low immunogenic risk are essential. Formulation development evaluates histidine concentration, pH, ionic strength, and compatibility with excipients such as polysorbates or sugars to achieve optimal stability profiles. Analytical stability studies assess whether histidine systems minimise oxidation, deamidation, or aggregation across storage conditions. Manufacturing considerations include buffer preparation control, microbial risk management, and consistency across batches. As high-concentration biologics for subcutaneous delivery become more common, histidine buffer optimisation remains important for ensuring stable, patient-friendly products.

Histidine Buffer refers to formulation systems using histidine as a buffering agent to maintain stable pH in pharmaceutical products, particularly biologics such as monoclonal antibodies and recombinant proteins. Histidine offers buffering capacity in physiologically relevant pH ranges and can support protein stability by reducing aggregation or degradation under certain conditions. Buffer selection influences product stability, compatibility with delivery devices, and patient tolerability.

The biopharmaceutical industry frequently employs histidine buffers in injectable biologic formulations where long-term stability and low immunogenic risk are essential. Formulation development evaluates histidine concentration, pH, ionic strength, and compatibility with excipients such as polysorbates or sugars to achieve optimal stability profiles. Analytical stability studies assess whether histidine systems minimise oxidation, deamidation, or aggregation across storage conditions. Manufacturing considerations include buffer preparation control, microbial risk management, and consistency across batches. As high-concentration biologics for subcutaneous delivery become more common, histidine buffer optimisation remains important for ensuring stable, patient-friendly products supporting reliable clinical performance.

Host Cell Protein (HCP) designates process-related impurities originating from the cells used to produce biologics, including residual proteins from expression hosts such as CHO cells, E. coli, or yeast. These impurities may persist through manufacturing and must be reduced to acceptable levels because they can impact product safety, immunogenicity, and stability.

The biopharmaceutical industry treats HCP control as a critical quality requirement in biologics manufacturing. Purification trains and process optimisation aim to remove HCPs effectively while maintaining product yield and integrity. Analytical testing commonly employs ELISA-based assays for total HCP quantification, alongside mass spectrometry methods identifying specific problematic proteins. Regulatory submissions include HCP clearance data and justification of acceptable limits, with ongoing monitoring ensuring batch consistency. Biosimilar developers must demonstrate comparable impurity profiles and robust HCP control strategies. As novel modalities and intensified processes emerge, HCP management remains essential for delivering safe, high-quality biologics.

Host Cell Protein (HCP) designates process-related impurities originating from the cells used to produce biologics, including residual proteins from expression hosts such as CHO cells, E. coli, or yeast. These impurities may persist through manufacturing and must be reduced to acceptable levels because they can impact product safety, immunogenicity, and stability. HCP profiles vary based on cell line, process conditions, and purification strategies.

The biopharmaceutical industry treats HCP control as a critical quality requirement in biologics manufacturing. Purification trains and process optimisation aim to remove HCPs effectively while maintaining product yield and integrity. Analytical testing commonly employs ELISA-based assays for total HCP quantification, alongside mass spectrometry methods identifying specific problematic proteins. Regulatory submissions include HCP clearance data and justification of acceptable limits, with ongoing monitoring ensuring batch consistency. Biosimilar developers must demonstrate comparable impurity profiles and robust HCP control strategies. As novel modalities and intensified processes emerge, HCP management remains essential for delivering safe, high-quality biologics with consistent performance.

Human Factors Engineering describes the discipline of designing medical products, devices, and interfaces to minimise user errors and improve safety by accounting for human capabilities, limitations, and real-world usage conditions. In biopharma, this is especially relevant for self-administered therapies using autoinjectors, prefilled syringes, inhalers, and wearable delivery systems.

The pharmaceutical industry integrates human factors engineering into combination product development to support safe and effective use across diverse patient populations. Studies assess usability risks such as incorrect injection technique, dose misreading, device handling challenges, or packaging confusion. Regulatory agencies require evidence that device designs mitigate foreseeable errors through appropriate labelling, training materials, and design controls. Human factors findings influence product design decisions including grip shape, force requirements, audible feedback, and step simplification. As patient-centric care expands and home administration becomes more common, human factors engineering increasingly determines real-world success of therapies.

Human Factors Engineering describes the discipline of designing medical products, devices, and interfaces to minimise user errors and improve safety by accounting for human capabilities, limitations, and real-world usage conditions. In biopharma, this is especially relevant for self-administered therapies using autoinjectors, prefilled syringes, inhalers, and wearable delivery systems. Human factors work evaluates how patients and healthcare professionals interact with devices under realistic conditions.

The pharmaceutical industry integrates human factors engineering into combination product development to support safe and effective use across diverse patient populations. Studies assess usability risks such as incorrect injection technique, dose misreading, device handling challenges, or packaging confusion. Regulatory agencies require evidence that device designs mitigate foreseeable errors through appropriate labelling, training materials, and design controls. Human factors findings influence product design decisions including grip shape, force requirements, audible feedback, and step simplification. As patient-centric care expands and home administration becomes more common, human factors engineering increasingly determines real-world success of therapies by improving adherence, reducing errors, and supporting consistent treatment outcomes.

Humanised Antibody designates engineered therapeutic antibodies combining complementarity-determining regions from non-human sources, typically mouse, with human framework regions and constant domains, reducing immunogenicity while retaining antigen-binding specificity. This protein engineering approach addresses limitations of mouse monoclonal antibodies that trigger human anti-mouse antibody responses limiting therapeutic utility.

The biopharmaceutical industry developed humanised antibodies as the second-generation therapeutic antibody format, with numerous products achieving blockbuster status treating cancer and autoimmune diseases. Design strategies include CDR grafting transferring only complementarity-determining regions, with framework mutations sometimes required restoring binding affinity. Computational modelling guides design predicting structures and identifying critical residues. Immunogenicity assessment evaluates anti-drug antibody formation in preclinical and clinical studies. Market success of humanised antibodies including trastuzumab and bevacizumab validated this approach and established therapeutic antibody utility. The humanised antibody legacy includes demonstrating feasibility of modifying immunogenicity through rational protein engineering.

Humanised Antibody designates engineered therapeutic antibodies combining complementarity-determining regions from non-human sources, typically mouse, with human framework regions and constant domains, reducing immunogenicity while retaining antigen-binding specificity. This protein engineering approach addresses limitations of mouse monoclonal antibodies that trigger human anti-mouse antibody responses limiting therapeutic utility through rapid clearance and potential allergic reactions. Humanisation methodologies transfer minimal non-human sequences necessary for antigen recognition into human antibody scaffolds.

The biopharmaceutical industry developed humanised antibodies as the second-generation therapeutic antibody format following mouse antibodies, with numerous products achieving blockbuster status treating cancer, autoimmune diseases, and other conditions. Design strategies include CDR grafting transferring only complementarity-determining regions, with framework mutations sometimes required restoring binding affinity. Resurfacing approaches modify surface-exposed residues predicted to trigger immune responses while maintaining internal structural residues. Computational modelling guides design predicting structures and identifying critical residues. Immunogenicity assessment evaluates anti-drug antibody formation in preclinical and clinical studies. Market success of humanised antibodies including trastuzumab and bevacizumab validated this approach. The humanised antibody legacy includes demonstrating feasibility of modifying immunogenicity through rational protein engineering while establishing therapeutic antibody utility across diverse diseases.

Humoral Immunity refers to immune protection mediated primarily by antibodies produced by B cells and plasma cells, enabling neutralisation of pathogens, opsonisation, and activation of complement pathways. This arm of the immune system plays central roles in vaccine effectiveness, protection against extracellular pathogens, and immune memory development.

The biopharmaceutical industry focuses heavily on humoral immunity in vaccine development, infectious disease therapeutics, and immunogenicity assessment for biologics. Vaccine trials measure antibody titres, neutralising activity, and durability of responses to demonstrate protective potential. Monoclonal antibody therapies harness humoral mechanisms by providing passive immunity or targeting disease-associated antigens. Immunogenicity monitoring evaluates whether therapeutic proteins trigger anti-drug antibodies that reduce efficacy or increase adverse events. Regulatory submissions often include humoral response data supporting efficacy claims and safety profiles. As next-generation vaccines and antibody-based platforms expand, understanding humoral immunity remains essential.

Humoral Immunity refers to immune protection mediated primarily by antibodies produced by B cells and plasma cells, enabling neutralisation of pathogens, opsonisation, and activation of complement pathways. This arm of the immune system plays central roles in vaccine effectiveness, protection against extracellular pathogens, and immune memory development. Humoral responses vary based on antigen exposure, individual immune status, and vaccine design.

The biopharmaceutical industry focuses heavily on humoral immunity in vaccine development, infectious disease therapeutics, and immunogenicity assessment for biologics. Vaccine trials measure antibody titres, neutralising activity, and durability of responses to demonstrate protective potential. Monoclonal antibody therapies harness humoral mechanisms by providing passive immunity or targeting disease-associated antigens. Immunogenicity monitoring evaluates whether therapeutic proteins trigger anti-drug antibodies that reduce efficacy or increase adverse events. Regulatory submissions often include humoral response data supporting efficacy claims and safety profiles. As next-generation vaccines and antibody-based platforms expand, understanding humoral immunity remains essential for designing effective interventions and predicting clinical outcomes.

Hybridoma designates immortalised cell lines created by fusing antibody-producing B lymphocytes with myeloma cells, combining B cell antibody production capabilities with myeloma immortality enabling indefinite monoclonal antibody secretion in culture. This breakthrough technology revolutionised antibody production, enabling generation of unlimited quantities of identical antibodies recognising specific antigens.

The biopharmaceutical industry historically depended on hybridoma technology for therapeutic antibody discovery, though limitations including mouse origin and production challenges led to alternative approaches. Hybridoma generation requires selecting fusion partners, employing selective media eliminating unfused cells, screening supernatants for antibody production, and cloning positive wells. Mouse antibodies from hybridomas proved immunogenic in humans, driving humanisation and fully human antibody technologies. The method remains valuable for research antibody production, diagnostic reagent generation, and preclinical studies. The hybridoma legacy includes demonstrating monoclonal antibody feasibility, enabling countless research advances, and establishing antibodies as major therapeutic modality.

Hybridoma designates immortalised cell lines created by fusing antibody-producing B lymphocytes with myeloma cells, combining B cell antibody production capabilities with myeloma immortality enabling indefinite monoclonal antibody secretion in culture. This breakthrough technology revolutionised antibody production, enabling generation of unlimited quantities of identical antibodies recognising specific antigens, replacing polyclonal antisera with defined reagents exhibiting consistent specificity. Hybridoma creation involves immunising animals, isolating antigen-specific B cells, fusing with myeloma cells, and screening resulting hybrids for desired antibody production.

The biopharmaceutical industry historically depended on hybridoma technology for therapeutic antibody discovery, though limitations including mouse origin and production challenges led to alternative approaches. Hybridoma generation requires selecting fusion partners, optimising fusion conditions, employing selective media eliminating unfused cells, screening supernatants for antibody production, and cloning positive wells ensuring monoclonality. Mouse antibodies from hybridomas proved immunogenic in humans, driving humanisation and fully human antibody technologies. Current applications include research antibody production, diagnostic reagent generation, and preclinical studies. Hybridoma technology enabled early therapeutic antibodies requiring subsequent humanisation and represents foundational technology launching the therapeutic antibody field. As recombinant antibody technologies advanced, hybridoma use declined for therapeutics though maintaining utility for research applications.

Hydrogel describes a three-dimensional network of hydrophilic polymers capable of absorbing large amounts of water while maintaining structural integrity, making it valuable for controlled drug delivery, tissue engineering, and wound care applications. Hydrogels can be engineered to respond to stimuli such as pH, temperature, or enzymatic activity, enabling targeted release profiles and improved local delivery.

The pharmaceutical industry develops hydrogel-based systems to improve delivery of drugs requiring sustained exposure, local administration, or protection from degradation. Injectable hydrogels enable minimally invasive delivery, forming depots that release therapeutics over extended periods while reducing dosing frequency. Regenerative medicine uses hydrogels as scaffolds supporting cell survival and tissue integration. Manufacturing and development require controlling polymer composition, crosslinking chemistry, degradation behaviour, and sterility assurance. As advanced delivery systems become more important for biologics and cell therapies, hydrogel technologies continue expanding as versatile platforms supporting innovative therapeutic strategies.

Hydrogel describes a three-dimensional network of hydrophilic polymers capable of absorbing large amounts of water while maintaining structural integrity, making it valuable for controlled drug delivery, tissue engineering, and wound care applications. Hydrogels can be engineered to respond to stimuli such as pH, temperature, or enzymatic activity, enabling targeted release profiles and improved local delivery. These materials may be natural, synthetic, or hybrid systems designed for biocompatibility and functional performance.

The pharmaceutical industry develops hydrogel-based systems to improve delivery of drugs requiring sustained exposure, local administration, or protection from degradation. Injectable hydrogels enable minimally invasive delivery, forming depots that release therapeutics over extended periods while reducing dosing frequency. Regenerative medicine uses hydrogels as scaffolds supporting cell survival and tissue integration. Manufacturing and development require controlling polymer composition, crosslinking chemistry, degradation behaviour, and sterility assurance. Regulatory evaluation considers both material safety and drug performance, particularly for combination products. As advanced delivery systems become more important for biologics and cell therapies, hydrogel technologies continue expanding as versatile platforms supporting innovative therapeutic strategies.

IND-Enabling Studies describe the set of preclinical experiments and development activities conducted to support submission of an Investigational New Drug application, allowing a candidate therapy to enter first-in-human clinical trials. These studies typically include pharmacology demonstrating biological activity, toxicology assessing safety margins, pharmacokinetic and pharmacodynamic profiling, and chemistry, manufacturing, and controls work establishing product quality.

The pharmaceutical industry designs IND-enabling packages to meet regulatory expectations while balancing speed, cost, and scientific confidence. Toxicology studies often include single-dose and repeat-dose assessments, safety pharmacology evaluating cardiovascular or respiratory effects, and evaluation of genotoxicity where relevant. Biologics may require specialised assessments for immunogenicity, cytokine release risk, or biodistribution. Manufacturing readiness includes process development, analytical method qualification, stability studies, and preparation of clinical-grade material under GMP. Successful IND-enabling studies represent a key milestone confirming programme maturity and readiness for clinical evaluation.

IND-Enabling Studies describe the set of preclinical experiments and development activities conducted to support submission of an Investigational New Drug application, allowing a candidate therapy to enter first-in-human clinical trials. These studies typically include pharmacology demonstrating biological activity, toxicology assessing safety margins, pharmacokinetic and pharmacodynamic profiling, and chemistry, manufacturing, and controls work establishing product quality and reproducibility. IND-enabling programmes generate sufficient evidence that a candidate can be administered to humans with acceptable risk under controlled clinical conditions.

The pharmaceutical industry designs IND-enabling packages to meet regulatory expectations while balancing speed, cost, and scientific confidence. Toxicology studies often include single-dose and repeat-dose assessments, safety pharmacology evaluating cardiovascular or respiratory effects, and evaluation of genotoxicity or reproductive toxicity where relevant. Biologics may require specialised assessments for immunogenicity, cytokine release risk, or biodistribution depending on modality. Manufacturing readiness includes process development, analytical method qualification, stability studies, and preparation of clinical-grade material under GMP. Successful IND-enabling studies represent a key milestone confirming programme maturity and readiness for clinical evaluation, enabling transition from laboratory discovery to human testing with appropriate regulatory oversight.

Immunoassay refers to analytical techniques using antibody-antigen interactions to detect and quantify biological molecules such as proteins, hormones, cytokines, or therapeutic drugs in complex samples. These assays provide high sensitivity and specificity, with common formats including enzyme-linked immunosorbent assays, chemiluminescent assays, lateral flow tests, and multiplex bead-based platforms. Immunoassays support clinical diagnostics, biomarker measurement, and biopharmaceutical product characterisation.

The biopharmaceutical industry employs immunoassays throughout discovery, development, and manufacturing to measure therapeutic concentrations, monitor immune responses, and support quality testing. Pharmacokinetic studies rely on immunoassays quantifying biologic drug levels in patient samples. Immunogenicity assessment uses immunoassays detecting anti-drug antibodies and neutralising antibodies. Biomarker programmes measure cytokines, soluble receptors, or pathway markers supporting mechanism of action validation. Manufacturing and quality control applications include potency assays, impurity detection, and lot release testing. Assay development requires optimisation for specificity, sensitivity, dynamic range, and matrix effects, while validation ensures accuracy, precision, and robustness.

Immunoassay refers to analytical techniques that use antibody-antigen interactions to detect and quantify biological molecules such as proteins, hormones, cytokines, or therapeutic drugs in complex samples. These assays provide high sensitivity and specificity, with common formats including enzyme-linked immunosorbent assays, chemiluminescent assays, lateral flow tests, and multiplex bead-based platforms. Immunoassays support clinical diagnostics, biomarker measurement, and biopharmaceutical product characterisation by enabling reliable quantification of analytes at low concentrations.

The biopharmaceutical industry employs immunoassays throughout discovery, development, and manufacturing to measure therapeutic concentrations, monitor immune responses, and support quality testing. Pharmacokinetic studies rely on immunoassays quantifying biologic drug levels in patient samples, informing dose selection and exposure-response relationships. Immunogenicity assessment uses immunoassays detecting anti-drug antibodies that may compromise treatment. Biomarker programmes measure cytokines, soluble receptors, or pathway markers supporting mechanism of action validation and patient stratification. Assay development requires optimisation for specificity, sensitivity, dynamic range, and matrix effects, while validation ensures accuracy, precision, and robustness. As biologic modalities expand and biomarker demands grow, immunoassays remain essential analytical tools supporting both clinical decision-making and product development.

Immunogenicity describes the ability of a therapeutic product to trigger an immune response in a patient, resulting in the formation of anti-drug antibodies or other immune-mediated reactions that may affect safety, efficacy, or pharmacokinetics. This phenomenon can occur with biologics including monoclonal antibodies, recombinant proteins, gene therapies, and cell therapies. Immunogenicity outcomes range from clinically insignificant antibody formation to severe effects including hypersensitivity reactions or loss of treatment response.

The biopharmaceutical industry evaluates immunogenicity as a critical safety and performance consideration throughout development. Preclinical risk assessment examines factors including sequence non-humanity, aggregation propensity, glycosylation patterns, formulation components, and manufacturing impurities. Clinical studies measure anti-drug antibodies, neutralising antibodies, and associated clinical impact. Risk mitigation approaches include protein engineering to increase human similarity, glycoengineering to avoid immunogenic glycans, improved purification processes, and formulation optimisation minimising aggregation. Regulatory submissions require immunogenicity assessment plans, validated assays, and interpretation of clinical relevance.

Immunogenicity describes the ability of a therapeutic product to trigger an immune response in a patient, resulting in the formation of anti-drug antibodies or other immune-mediated reactions that may affect safety, efficacy, or pharmacokinetics. This phenomenon can occur with biologics including monoclonal antibodies, recombinant proteins, gene therapies, and cell therapies, as the immune system may recognise therapeutic molecules or their impurities as foreign. Immunogenicity outcomes range from clinically insignificant antibody formation to severe effects including hypersensitivity reactions, loss of treatment response, or neutralisation of endogenous proteins.

The biopharmaceutical industry evaluates immunogenicity as a critical safety and performance consideration throughout development and post-marketing use. Preclinical risk assessment examines factors influencing immunogenicity including sequence non-humanity, aggregation propensity, glycosylation patterns, and manufacturing impurities. Clinical studies measure anti-drug antibodies, neutralising antibodies, and associated clinical impact such as altered drug exposure or reduced efficacy. Risk mitigation approaches include protein engineering to increase human similarity, glycoengineering, improved purification processes reducing impurities, and formulation optimisation minimising aggregation. Regulatory submissions require immunogenicity assessment plans, validated assays, and interpretation of clinical relevance. As biologics become increasingly complex, immunogenicity management remains essential for ensuring therapeutic consistency and sustained clinical benefit.